Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: Results of an European Experts Panel

Annals of Oncology

Volumn 15, Issue 3, 2004, Pages 419-426

  Gridelli, C ^a   Ardizzoni, A ^b   Le Chevalier, T ^c   Manegold, C ^d   Perrone, F ^e   Thatcher, N ^f   van Zandwijk, N ^g   Di Maio, M ^e   Martelli, O ^h   De Marinis, F ^h  

^a S G MOSCATI HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Thoraxklinik ^*  (Germany)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f CHRISTIE HOSPITAL   (United Kingdom)

^g NETHERLANDS CANCER INSTITUTE   (Netherlands)

^h SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Advanced disease; Chemotherapy; Consensus; Non small cell lung cancer; Performance status 2

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; IFOSFAMIDE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; VINDESINE;

ANEMIA; CANCER PATIENT; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; EUROPE; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HEALTH STATUS; HEMATOLOGIC DISEASE; HUMAN; ITALY; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; MEDICAL EXPERT; META ANALYSIS; NAUSEA AND VOMITING; NEUTROPENIA; PATIENT CARE; PHASE 3 CLINICAL TRIAL; PHYSICAL CAPACITY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; STANDARDIZATION; SYMPTOM; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 11144357752     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh087     Document Type: Review

References (49)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543.
2. Borras JM, Fernandez E, Gonzalez JR et al. Lung cancer mortality in European regions (1955-1997). Ann Oncol 2003; 14: 159-161.
3. Tyczynski JE, Bray F, Parkin DM. Lung cancer in Europe in 2000: Epidemiology, prevention, and early detection. Lancet Oncol 2003; 4: 45-55.
4. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In Macleod CM (ed.): Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press 1949; 199-205.
5. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
6. Le Chevalier T, Brisgand D, Douillard JY et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-367.
7. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2002; 346: 92-98.
8. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. Italian Lung Cancer Project. J Clin Oncol 2002; 20: 4285-4291.
9. Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95: 362-372.
10. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996; 32A: 1135-1141.
11. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 651 cases. Ann Oncol 2002; 13: 1087-1093.
12. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
13. ASCO Special Article. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997; 15: 2996-3018.
14. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol 2001; 12: 1049-1050.
15. Bunn PA Jr. Chemotherapy for advanced non-small-cell lung cancer: Who, what, when, why? J Clin Oncol 2002; 20 (18 Suppl): 23S-33S.
16. Lewis JH, Kilgore ML, Goldman DP et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21: 1383-1389.
17. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-2067.
18. Yusef S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266: 93-98.
19. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65: 25-32.
20. Albain KS, Crowley JJ, LeBlanc M et al. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618-1626.
21. Takigawa N, Segawa Y, Okabara M et al. Prognostic factors for patients with advanced non-small cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer 1996; 15: 67-77.
22. Ando M, Ando Y, Sugiura S et al. Prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer. Jpn J Cancer Res 1999; 90: 249-253.
23. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: A decade of progress. Chest 2002; 122: 1037-1057.
24. Socinski MA, Morris DE, Masters GA, Lilenbaum R. Chemotherapeutic management of stage IV non-small cell lung cancer. American College of Chest Physicians. Chest 2003; 123 (1 Suppl): 226S-243S.
25. Jiroutek M, Johnson D, Blum R et al. Prognostic factors in advanced non-small-cell lung cancer: Analysis of Eastern Cooperative Oncology Group trials from 1981-1992. Proc Am Soc Clin Oncol 1998; 17: 461 (Abstr 1774).
26. Cullen MH, Billingham LJ, Woodroffe CM et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17: 3188-3194.
27. Sweeney CJ, Zhu J, Sandler AB et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: A phase II trial in patients with metastatic non-small cell lung carcinoma. Cancer 2001; 92: 2639-2647.
28. Crinò L, Novello S, Migliorino MR et al. A phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer (NSCLC): Impact of PS = 2 vs 0 or 1 and age >70 vs <70 on chemotherapy outcome. Proc Am Soc Clin Oncol 2002; 21: 315a (Abstr 1258).
29. Billingham LJ, Cullen MH. The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer. Ann Oncol 2001; 12: 1671-1675.
30. Stephens RJ, Fairlamb D, Gower N et al. The Big Lung Trial (BLT): Determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting. Proc Am Soc Clin Oncol 2002; 21: 291a (Abstr 1161).
31. Anderson H, Hopwood P, Stephens RJ et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: A randomized trial with quality of life as the primary outcome. Br J Cancer 2000; 83: 447-453.
32. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non small cell lung cancer. J Natl Cancer Inst 1999; 91: 66-72.
33. Ranson M, Davidson N, Nicolson M et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92: 1074-1080.
34. Roszkowski K, Pluzanska A, Krzakowski M et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27: 145-157.
35. Slevin ML, Stubbs L, Plant HJ et al. Attitudes to chemotherapy: Comparing view of patients with cancer with those of doctors, nurses and general public. BMJ 1990; 300: 1458-1460.
36. Soria J-C, Brisgand D, Le Chevalier T. Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy? Ann Oncol 2001; 12: 1667-1670.
37. Lilenbaum RC, Herndon J, List M et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer a CALGB randomized trial of efficacy, quality of life, and cost-effectiveness. Proc Am Soc Clin Oncol 2002; 21: 1a (Abstr 2).
38. Georgoulias V, Papadakis E, Alexopoulos A et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial. Lancet 2001; 357: 1478-1484.
39. Kosmidis P, Mylonakis N, Nicolaides C et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer. a phase III randomized trial. J Clin Oncol 2002; 20: 3578-3585.
40. Giaccone G. Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975. Semin Oncol 2002; 29 (3 Suppl 9): 47-49.
41. Alberola V, Camps C, Provencio M et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003; 21: 3207-3213.
42. Gridelli C, Gallo C, Shepherd FA et al. Gemcitabine plus vinorelbine compared to cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer. A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2003; 21: 3025-3034.
43. Fukuoka K Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-2246.
44. Kris MG, Natale RB, Herbst RS et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small-cell lung cancer patients who had failed platinum-and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002; 21: 292a (Abstr 1166).
45. Douillard JY, Giaccone G, Horai T et al. Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer treated with ZD 1839 ('Iressa') (IDEAL 1). Proc Am Soc Clin Oncol 2002; 21: 299a (Abstr 1195).
46. Natale RB, Skarin AT, Maddox AM et al. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. Proc Am Soc Clin Oncol 2002; 21:292a (Abstr 1167).
47. Perrone F, Gallo C, Gridelli C. Re: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern. Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94: 1029-1030.
48. PDQ National Cancer Institute Clinical Trials Database. Available online at: Http://www.cancer.gov/clinical_trials (date last accessed: 30 April 2003).
49. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small-cell lung cancer: descriptive study based on scripted interviews. BMJ 1998; 317: 771-775.